Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
ConditionObesity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16-70
SponsorChina-Japan Friendship Hospital
About this trial
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits.
Given the lack of multi-regional validation in China's diverse population, this multicenter study aims to confirm the real-world effectiveness and generalizability of bariatric surgery plus GLP-1RA across distinct regional cohorts.
Eligibility criteria
Qualifiers
Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
obesity:BMI ≥27.5 kg/m².
Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
Age range: 16-70 years (inclusive).
Disqualifiers
Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
Trial design
Treatments tested in this trial
- BS-GLP1RA group
- BS group
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov